Hikma Pharmaceuticals faces tougher path to re-rating
AlphaValue flags a harder route to a re-rating for Hikma after applying a wider peer discount and a c.7% Target price reduction, citing a lowered profitability outlook, supply chain issues at Bedford, Geographic Expansion pressure, management change, and limited biosimilars capability despite United States partnerships.
Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows:
- generic injectable products (41.8%);
- generic products taken orally (32.8%);
- brand name drugs (24.68%);
- other (0.8%).
Net sales are distributed geographically as follows: the United Kingdom (0.4%), the United States (61.1%), Middle East and North Africa (31.5%) and other (7%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
This Alphavalue article, the European leader in independent research, is only available to subscribers .
